Documentos de Académico
Documentos de Profesional
Documentos de Cultura
TITULO polineuropatia
II.
III.
IV.
V.
CARACTERISTICAS
DISTINTIVAS
DE
ESTRUCTURALES EN LA DIABETES MELLITUS
Diabticos tipo I
Tumefaccin paranodal
Disyuccinaxioglial
Atrofia axonal
LAS
LESIONES
Diabticos tipo II
Degeneracin axonal
Degeneracin Walleriana
Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. J DiabetComplications 1992;6:49-57.
Proceedings of a Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Diabetes Care
1992;15:1080-107.
Maser RE, Steenkiste AR, Dorman JS. Epidemiological correlates of diabetic neuropathy. ReportfromPittisburghEpidemiology
of Diabetes ComplicationsStudy. Diabetes 1989;38:1456-61.
Franklin GM, Kahn LB, Baxter J. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Valley Diabetes
Study. Am J Epidemiol 1990;131-43.
5.
6.
7.
8.
9.
Ziegler D, Gries FA, Muhlen H, Rathmann W, Spuler M, Lessmann F. Prevalence and clinical correlates of cardiovascular
autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. DiabeteMetab 1993;143-51.
Ziegler D, Dannehl K, Spuler M, Muhlen H, Gries FA. Prevalence of cardiovascular autonomic nerve dysfunction assessed by
spectral analysis and standard tests of hearth rate variation in newly diagnosed IDDM patients. Diabetes Care 1992;15:908-11.
Dyck PJ, O'Brien PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of
diabetic neuropathy. Diabetes Care 1989;12:649-52.
Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton III LJ. The Rochester Diabetic Neuropathy Study: reassessment of
test and criteria for diagnosis and staged severity. Neurology 1992;42:1164-70.
Valk JJP, Nauta RLM, Strijer RLM, Bertelsmann FW. Clinical examinations versus neurophysiological examination in the
diagnosis of diabetic polyneuropathy. DiabetMed 1992;9:716-21.
10. Ross MA. Neuropathies associated with diabetes. MedClin North Am 1993;77:111-24.
11. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetic. MuscleNerve 1988;11:21-32.
12. Sima AAF, Lattimer SA, Yagihashi S. Axo-glial dysjuntion: a novel structural lesion that accounts for poorly reversible slowing
of never conduction impulse in the spontaneously diabetic Bio-breeding rat. J ClinInvest 1986;77:474-84.
13. Sima AAF. Structure-funtion interactions in the therapeutic response of diabetic neurophaty. J DiabComp 1992;6:40-4.
14. Sima AAF, Nathaniel V, Bril V, McEwen AJ, Greene DA. Histopathological heterogeneity in insulin-dependent and non-insulindependent diabetes, and demostration of axo-glial dysjunction in human diabetic neuropathy. J ClinInvest 1988;81:349-64.
15. Sima AAF, Zhang W-X, Tai J, Tze WJ, Nathaniel V. Diabetic neuropathy in STZ-induced diabetic rat and effect of allogenic islet
cell transplantation: a morphometric analysis. Diabetes 1988;37:1129-36.
16. Lattimer SA, Sima AAF, Greene DA. In vitro correlation of impaires Na+-K+-ATPase in diabetic nerve by protein kinase C
agonist. Am J Physiol 1989;256:E264-9.
17. Yorek MA, Dunlap JA, Leewney EM. Effect of galactose and glucose levels and sorbinil treatment on myo-inositol metabolism
and Na+-K+- pump activity in cultures neuroblastoma cells. Diabetes 1989;996-1004.
18. Sima AAK, Brismar T. Reversible diabetic nerve dysfunction: structural correlates to electrophysiological adnormalities. Ann
Neurol 1985;18:21-9.
19. Sima AAF, Prashar A, Zhang W-X. The preventive effect of long-term aldose reduction inhibitors (Ponalrestat) an nerve
conduction and sural nerve structure in the spontaneously diabetic BB-rat. J ClinInvest 1990;85:1410-20.
20. Sima AAF, Bril V, Nathaniel V. Regeneration and repair of myelenated fibres in sural nerve biopsy specimens from patients with
diabetic neuropathy treated with sorbinil. N Engl J Med 1988;319:548-55.
21. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenic considerations. Diabetes
Care 1992;15:1902-25.
22. Fisher SK, Heacock AM, Agranoff BW. Inositol lipids and signal transductions in the nervous system: an update. J Neurochem
1992;58:18-38.
23. Del Monte MA, Rabbani R, Diaz TC, Lattimer SA. Sorbitol, myo-inositol and rod outer segment phagacytosis in glucoseexposed cultures human retinal pigment epitelial cells: in vitro modeling of the myo-inositol deplection hypothesis of diabetic
complications. Diabetes 1991;40:1335-45.
24. Greene DA, Lattimer-Greene SA, Sima AAF. Pathogenesis of diabetic neuropathy: role of altered phosphoinositide metabolism.
CritRevNeurobiol 1989;5:143-219.
25. Lee TS, Slatsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: proposal for a
mechanism in the development of diabetic vascular comnplications. ProcNatlAcadSci USA 1989;86:5141-5.
26. Simmons
DA, Winegrand AI. Mechanism of glucose-induced (Na+-K+) -ATPase inhibition in aortic wall of rabbits.
Diabetologa 1989;32:402-8.
27. Hirata T, Okada K. Relations of Na+-K+-ATPase to delayed motor nerve conduction velocity: effect of aldose reductase
inhibitor, ADN-138, on Ka+-K+-ATPase activity. Metabolism 1990;39:563-7.
28. Malik RA, Masson EA, Sharma AK. Hypoxic neuropathy: relevance to human diabetic neuropathy. Diabetologa 1990;33:311-8.
29. Low PA, Kihara M, Cameron N, Cotter J, Poduslo J. Cause and effect of ischemia in chronic experimental diabetic neuropathy.
DiabeticMed 1993;10:52S-55S.
30. Tesfaye S, Harris N, Wilson RM, Ward JD. Exercise induced conduction velocity increment: a marker of impaired blood flow in
diabetic neuropathy. Diabetologa 1992;35:155-9.
31. Tesfaye S, Malik R, Harris N, Jakubowski J, Mody C, Ward JD. Painful and severe autonomic neuropathy following insulin:
futher evidence for microvascular disease in neuropathy. Diabetes 1993;42:196A.
32. Tesfaye S, Harris N, Jakubowski JJ, Mody C, Wilson RM, Rennie IG. Impaired blood flow and arterio-venous shunting in human
diabetic neuropathy. Diabetologa 1993;36:1266-74.
33. Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy.
IntRevNeurobiol 1989;31:355-438.
34. Tesfaye S, Malik R, Ward JD. Vascular Factors in diabetic neuropathy. Diabetologa 1994;37:847-54.
35. Yang H, Scheff AJ, Schalch DS. Effects of streptozotocin-induced diabetes mellitus on growth and hepatic insulin-like growth
factor I gene expresion in the rat. Metabolism 1990:39:295-301.
36. Luo J, Murphy LJ. Differential expresions of insulin-like growth factor binding protein-1 in the diabetical rat. Mol CellBiochem
1991;103:41-50.
37. Oppenheim RW, Prevette D, Qin-Wei Y, Collins F, MacDonald J. Control of embryonic motoneuron survival in vivo by ciliary
neurotrophic factor. Science 1991;251:1616-8.
38. Romero JC, Licea A, Mallea L, Hernndez A, Almaraz MC. Concentraciones plasmticas de lpidos y fibringeno en diabticos
tipo I con microalbuminuria. Endocrinologa 1993;40:148-52.
39. MacRury SM, Lowe GDO. Blood rheology in diabetes mellitus. DiabMed 1990;7:285-91.
40. MacRury SM, Lockhart JC, Small M, Weir AI, MacCuish AC, Lowe GDO. Do rheological variables play a role in diabetic
peripheral neuropathy. DiabMed 1991;8:232-6.
Recibido:25 de septiembre de 1995. Aprobado: 9 de noviembre de 1995.
Dr. Juan Carlos Romero Mestre. Instituto Nacional de Endocrinologa, Zapata y D, Vedado, Ciudad de La Habana, Cuba.